IQN Path and City Cancer Challenge partner to address global barriers to precision oncology
IQN Path is announcing a strategic technical collaboration with City Cancer Challenge (C/Can) to reinforce diagnostic infrastructure and expertise in low- and middle-income countries (LMICs), where access to precision oncology remain mostly limited. The global diagnostic gap Precision medicine in oncology is advancing rapidly, offering patients a growing number of targeted treatments based on individual read more…
Biomarker Testing on Cytology Samples – Global Survey
IQN Path is pleased to endorse this important international survey on cytology-based biomarker testing. Laboratories worldwide are invited to take part. The survey, which is being led by dr. Irena Srebotnik Kirbis (Faculty of Medicine, University of Ljubljana) with the collaboration of UK NEQAS and GenQA, aims to capture current cytology processing practices. This information will be used to design read more…
New Paper in The Journal of Liquid Biopsy: “BLOODPAC’s collaborations with European Union liquid biopsy initiatives”
BLOODPAC’s collaborations with European Union liquid biopsy initiatives The adoption of liquid biopsy into clinical practice has revolutionized the landscape of cancer diagnostics and treatment monitoring. In the U.S., the Blood Profiling Atlas in Cancer (BLOODPAC) has significantly supported the advancement of these technologies through consensus building [1]. In collaboration with the United States (US) read more…
New Paper in PubMed: “Indirect clinical validation for predictive biomarkers in oncology: International Quality Network for Pathology (IQN Path) Position Paper”
Indirect clinical validation for predictive biomarkers in oncology: International Quality Network for Pathology (IQN Path) Position Paper Validation of biomarker assays is mandatory not only for their applications in clinical trials but also for their subsequent transfer to clinical laboratories in routine clinical care. There are two critical components relevant to their transfer to clinical read more…
HER2-LOW EDUCATIONAL WEB-PORTAL
This project is sponsored by IQN Path and provided by the UK NEQAS ICC & ISH. The results of the DESTINY-Breast 04 phase-3 clinical trial provided evidence that HER2-Low expressing breast cancer responded to treatment using the antibody-drug conjugate. trastuzumab deruxtecan (T-DXd) therapy [1] . As a result of the trial’s findings, the FDA approved read more…
IQN Path contributed to a report by the IHE on cancer inequalities
Tackling inequalities in cancer care in the European Union IQN Path contributed to the report published by the IHE – The Swedish Institute for Health Economics with an insight on access to biomarker testing and precision medicine in Europe. Read it here: https://ihe.se/en/rapport/tackling-inequalities-in-cancer-care-in-the-european-union-2/
New paper in Virchows Archiv: “External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme”
External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme Tumor mutational burden (TMB) has recently been approved as an agnostic biomarker for immune checkpoint inhibitors. However, methods for TMB testing have not yet been standardized. The International Quality Network for Pathology (IQNPath) organized a pilot external quality read more…
New paper in European Journal of Cancer: “Access and quality of biomarker testing for precision oncology in Europe”
Abstract Background Predictive biomarkers are essential for selecting the best therapeutic strategy in patients with cancer. The International Quality Network for Pathology, the European Cancer Patient Coalition and the European Federation of Pharmaceuticals Industries and Associations evaluated the access to and quality of biomarker testing across Europe. Methods Data sources included surveys of 141 laboratory managers and read more…